Treatment of disease conditions through modulation of hydrogen sulfide produced by small intestinal bacterial overgrowth 机翻标题: 暂无翻译,请尝试点击翻译按钮。

公开号/公开日
WO2006102536 A2 2006-09-28 [WO2006102536]WO2006102536 A3 2007-05-03 [WO2006102536] / 2006-09-282007-05-03
申请号/申请日
2006WO-US10641 / 2006-03-23
发明人
LIN HENRY C;
申请人
UNIVERSITY OF SOUTHERN CALIFORNIA;
主分类号
IPC分类号
A01N-063/00A61K-049/00
摘要
(WO2006102536) The present invention relates to the treatment of a wide array of diseases and physiologic conditions based on modulating the level of hydrogen sulfide (H2S) in the body by at least partially eradicating small intestinal bacterial overgrowth (SIBO) in the gut.  An H2S or lactulose breath test and/or detection of H2S or thiosulfate in the blood or urine may be used as a diagnostic and/or prognostic for assessing a systemic H2S load that exceeds a mammal's natural detoxification capacity.  These tests may similarly be used to monitor the effectiveness of a therapeutic intervention for SIBO and/or the diseases or physiologic conditions whose pathology is linked thereto.  Because SIBO is related to hyperhomocysteinemia, diseases and physiologic conditions that relate to hyperhomocysteinemia may further be monitored and treated in connection with the methods of the present invention.
机翻摘要
暂无翻译结果,您可以尝试点击头部的翻译按钮。
地址
代理人
代理机构
;
优先权号
2005US-60664599 2005-03-23
主权利要求
(WO2006102536) WHATIS CLAIMED IS: 1. A method for treating a disease condition in a mammal with an elevated level of bacteria-derived hydrogen sulfide (H2S), comprising: providing a therapeutic agent capable of at least partially eradicating the bacterial overgrowth to reduce the level of bacteria-derived H2S in the mammal; and administering the therapeutic agent to the mammal, wherein the disease condition is a disease condition related to a category selected from the group consisting of hypercoagulable states related to hyperhomocysteinemia, vasodilatator states, interference with function as neurotransmitter, interference with endocrine function, chronic pain syndromes due to stimulation of N-methyl-D-aspartate (NMDA) receptors leading to hypersensitivity, injury to nasal and/or respiratory tract, interference with visceral smooth muscle contractile function, inhibition of aerobic metabolism/ischemia disorders, triggering of inflammation, overlap disorders, interference with regulation of apoptosis and proliferation and combinations thereof. 2. The method of claim 1 , wherein the disease condition is selected from the group consisting of hyperhomocysteinemia, chronic renal failure, end stage renal disease, hemodialysis, peritoneal dialysis, vascular dementia, cardiovascular disease, stroke, cerebrovascular accidents, thrombotic disorder, hypercoagulable states, venous thrombosis, deep vein thrombosis, thrombophlebitis, thromboembolic disease, ischemic stroke, restenosis after percutaneous transluminal coronary angioplasty (PTCA), preeclampsia, vasculitis, digital ischemia, multifocal osteonecrosis, retinal vein occlusion, glaucoma, miscarriage, pregnancy complication, placental abruption, transplantation, diabetic retinopathy, ischemic bowel disease, cerebral vein thrombosis, atherosclerosis, coronary artery disease, penile venous thrombosis, impotence, central venous thrombosis, peripheral artery disease, intermittent claudication, hemorrhagic colitis, radiation enteritis, radiation colitis, visceral ischemia, acute mesenteric ischemia, chronic mesenteric ischemia, hypertension, microangiopathy, macroangiopathy, recurrent leg ulcer, carotid stenosis, occlusive vascular disease, arterial aneurysm, abdominal aortic aneurysm, congestive heart failure, hepatopulmonary syndrome, high flow state associated with chronic liver disease, migraine headache, vascular headache, dizziness, lightheadedness, orthostatic intolerance, postural hypotension, postural hypotension, postural orthostatic tachycardia syndrome, idiopathic pulmonary fibrosis, pulmonary hypertension, angioedema, vaso-vagal faints, neuroleptic malignant syndrome, learning disorder, learning disability, insomnia, dementia, age associated memory impairment, attention deficit/hyperactivity disorder (ADHD), mild cognitive impairment, Alzheimer's disease, Down's syndrome, autism, Parkinson's disease, depression, anxiety or anxiety disorder, Asperger syndrome, glucose intolerance, diabetes, reactive hypoglycemia, metabolic syndrome, low Cortisol, hypothalamus- pituitary-adrenal dysfunction, myasthenia gravis syndrome, osteoporosis, autoimmune polyendocrine syndrome, chronic fatigue syndrome (CFS)5central sensitivity syndrome, angina, syndrome X, chronic neck pain syndrome, chronic neuromuscular pain, osteoarthritis, muscle tension headache, chronic headache, cluster headache, temporalis tendonitis, sinusitis, atypical facial pain, trigeminal neuralgia, facial and neck pain syndrome, temperomandibular joint syndrome, idiopathic chronic low back pain, endometriosis, painful abdominal adhesions, chronic abdominal pain syndrome, coccydynia, pelvic floor myalgia (levator ani spasm), polymyositis, postherpetic neuralgia, polyradiculoneuropathies, mononeuritis multiplex, reflex sympathetic dystrophy, neuropathic pain, vulvar vestibulitis, vulvodynia, chronic regional pain syndrome, osteoarthritis, fibrositis, chronic visceral pain syndrome, female urethral syndrome, painful diverticular disease, functional dyspepsia, nonulcer dyspepsia, non- erosive esophageal reflux disease, acid-sensitive esophagus, interstitial cystitis, chronic pelvic pain syndrome, chronic urethral syndrome, chronic prostatitis, primary dysmenorrhea!, dyspareunia, premenstrual syndrome (PMS), vulvodynia, ovarian remnant syndrome, ovulatory pain, pelvic congestion syndrome, myofasical pain syndrome, fibromyalgia polymyalgia rheumatica, Reiter's syndrome (reactive arthritis), rheumatoid arthritis, spondyloarthropathy, functional somatic syndromes, chronic regional pain syndromes, post polio syndrome, functional somatic syndrome, rhinitis, asthma, multiple chemical sensitivity syndrome, reactive airway dysfunction syndrome, dysnomia, sick building syndrome, asthma, idiopathic pulmonary fibrosis, idiopathic pulmonary hypertension, dysphagia, gastroparesis, functional diarrhea, chronic constipation, defecation dysfunction, dysuria, atonic bladder, neurogenic bladder, irritable bowel syndrome (IBS), ileus, chronic idiopathic pseudoobstruction, Ogilvie's syndrome, restless leg syndrome, immune dysfunction syndrome, multiple sclerosis (MS), eczema, psoriasis, atopic dermatitis, dermatitis, Crohn's disease, ulcerative colitis, ulcerative proctitis, pouchitis, nonspecific ulcerative colitis, inflammatory bowel disease (IBD), celiac disease, diversion colitis, collagenous colitis, lymphocytic colitis, blind loop syndrome, nonalcoholic steatohepatitis (NASH), fatty liver, chronic liver disease, cirrhosis, spontaneous bacterial peritonitis, postoperative ileus, systemic lupus erythematosis, mixed connective tissue disorder, undifferentiated connective tissue disorder, Raynaud's phenomenon, Kawasaki syndrome, polymyositis, dermatomyositis, myositis, multiple autoimmune syndrome, Sjogren's syndrome, lichen planus, idiopathic uveitis, gingivitis, stomatitis, otitis, necrotizing enterocolitis, intensive care unit (ICU) multiple organ failure, primary biliary cirrhosis, idiopathic myelofibrosis, polyarteritis nodosa, eosinophilic pleural effusion, eosinophilic gastroenteritis, eosinophilic esophagitis, graft vs. host disease, Grave's disease, idiopathic thyroid failure, Hashimoto's thyroiditis, autoimmune hepatitis, pancreatitis, CREST syndrome, autoimmune cholangitis, ankylosing spondylitis, atopic dermatitis, vitiligo, scleroderma, autoimmune ear disease, polyangiitis overlap syndrome, primary sclerosing cholangitis, Gulf War syndrome, myalgic encephalomyelitis, food sensitivity, dysregulation spectrum syndrome, post-traumatic stress disorder (PTSD), benign tumor, malignant tumor, cancer and combinations thereof. 3. The method of claim 1 , wherein the therapeutic agent is a therapeutic agent capable of at least partially eradicating the bacterial overgrowth of sulfur-reducing bacteria. 4. The method of claim 3, wherein the therapeutic agent capable of at least partially eradicating the bacterial overgrowth of sulfur-reducing bacteria is a methanogenic bacterium that out-competes the sulfur-reducing bacteria. 5. The method of claim 1 , wherein the therapeutic agent is selected from the group consisting of an antimicrobial agent, an antimicrobial chemotherapeutic agent, an intestinal lavage agent, an enema agent, a bismuth-containing compound, a compound that binds iron in the intestinal lumen, a compound that binds hydrogen sulfide, a probiotic agent, an agent that increases the mammal's phase III interdigestive intestinal motility and combinations thereof. 6. The method of claim 5, wherein the antimicrobial agent is selected from the group consisting of a natural antibiotic agent, a synthetic antibiotic agent, a semi-synthetic antibiotic agent and combinations thereof. 7. The method of claim 5, wherein the antimicrobial agent is selected from the group consisting of neomycin, metronidazole, teicoplanin, doxycycline, tetracycline, norfloxacin, ciprofloxacin, augmentin, cephalexin, penicillin, ampicillin, kanamycin, rifamycin, rifaximin, vancomycin and combinations thereof. 8. The method of claim 5, wherein the antimicrobial chemotherapeutic agent is a 4- aminosalicylate compound or a 5-aminosalicylate compound. 9. The method of claim 5, wherein the antimicrobial chemotherapeutic agent is selected from the group consisting of 4-(p)-aminosalicylic acid, 4-(p)-aminosalicylate sodium salt, 5-aminosalicylic acid, conjugated derivatives thereof, conjugated bile acids thereof and combinations thereof. 10. The method of claim 5, wherein the probiotic agent is selected from the group consisting of a Bifidobacterium species, a Lactobacillus species and combinations thereof. 11. The method of claim 5, wherein the probiotic agent is selected from the group consisting of L. acidophilus, L. rhamnosus, L. plantarum, L reuteri, L. paracasei, L. casei Shirota, L. salivarius, B. infantis and combinations thereof. 12. The method of claim 5, wherein the agent that increases the mammal's phase III interdigestive intestinal motility is a prokinetic agent. 13. The method of claim 12, wherein the prokinetic agent is selected from the group consisting of a bile acid, a bile salt, a prokinetic peptide, a macrolide compound, a 5- hydroxytryptamine receptor directed drug, a 5-HT4 receptor agonist, a 5-HT receptor antagonist, a compound with cholinergic activity, a dopamine antagonist, a nitric oxide altering agent, an antihistamine, a neuroleptic agent, a kappa agonist and combinations thereof. 14. The method of claim 12, wherein the prokinetic agent is selected from the group consisting of motilin, erythromycin, azithromycin, tegaserod, ondansetron, cilansetron, granisetron, alosetron, ursodeoxycholic acid, chenodeoxycholic acid, a salt of ursodeoxycholate, a salt of chenodeoxycholate, cisapride, metoclopramide, domperidone, bethanechol, octreotide, cholecystonin, nitroglycerin, nomega-nitro-L-arginine methylester (L-NAME), N-monomethyl-L-arginine (L-NMMA), promethazine, meclizine, prochlorperazine, chlorpromazine, haloperidol and combinations thereof. 15. A method for diagnosing and/or determining the prognosis of a disease condition related to an elevated level of bacteria-derived hydrogen sulfide (H2S) in a mammal having at least one symptom associated with a suspected diagnosis of the disease condition, comprising: detecting the presence and/or concentration of hydrogen sulfide (H2S) and/or thiosulfate; and diagnosing and/or determining the prognosis of the disease condition, wherein the disease condition is a disease condition related to a category selected from the group consisting of hypercoagulable states related to hyperhomocysteinemia, vasodilatator states, interference with function as neurotransmitter, interference with endocrine function, chronic pain syndromes due to stimulation of N-methyl-D-aspartate (NMDA) receptors leading to hypersensitivity, injury to nasal and/or respiratory tract, interference with visceral smooth muscle contractile function, inhibition of aerobic metabolism/ischemia disorders, triggering of inflammation, overlap disorders interference with regulation of apoptosis and proliferation and combinations thereof. 16. The method of claim 15 , wherein the disease condition is selected from the group consisting of hyperhomocysteinemia, chronic renal failure, end stage renal disease, hemodialysis, peritoneal dialysis, vascular dementia, cardiovascular disease, stroke, cerebrovascular accidents, thrombotic disorder, hypercoagulable states, venous thrombosis, deep vein thrombosis, thrombophlebitis, thromboembolic disease, ischemic stroke, restenosis after percutaneous transluminal coronary angioplasty (PTCA), preeclampsia, vasculitis, digital ischemia, multifocal osteonecrosis, retinal vein occlusion, glaucoma, miscarriage, pregnancy complication, placental abruption, transplantation, diabetic retinopathy, ischemic bowel disease, cerebral vein thrombosis, atherosclerosis, coronary artery disease, penile venous thrombosis, impotence, central venous thrombosis, peripheral artery disease, intermittent claudication, hemorrhagic colitis, radiation enteritis, radiation colitis, visceral ischemia, acute mesenteric ischemia, chronic mesenteric ischemia, hypertension, microangiopathy, macroangiopathy, recurrent leg ulcer, carotid stenosis, occlusive vascular disease, arterial aneurysm, abdominal aortic aneurysm, congestive heart failure, hepatopulmonary syndrome, high flow state associated with chronic liver disease, migraine headache, vascular headache, dizziness, lightheadedness, orthostatic intolerance, postural hypotension, postural hypotension, postural orthostatic tachycardia syndrome, idiopathic pulmonary fibrosis, pulmonary hypertension, angioedema, vaso-vagal faints, neuroleptic malignant syndrome, learning disorder, learning disability, insomnia, dementia, age associated memory impairment, attention deficit/hyperactivity disorder (ADHD), mild cognitive impairment, Alzheimer's disease, Down's syndrome, autism, Parkinson's disease, depression, anxiety or anxiety disorder, Asperger syndrome, glucose intolerance, diabetes, reactive hypoglycemia, metabolic syndrome, low Cortisol, hypothalamus- pituitary-adrenal dysfunction, myasthenia gravis syndrome, osteoporosis, autoimmune polyendocrine syndrome, chronic fatigue syndrome (CFS), central sensitivity syndrome, angina, syndrome X, chronic neck pain syndrome, chronic neuromuscular pain, osteoarthritis, muscle tension headache, chronic headache, cluster headache, temporalis tendonitis, sinusitis, atypical facial pain, trigeminal neuralgia, facial and neck pain syndrome, temperomandibular joint syndrome, idiopathic chronic low back pain, endometriosis, painful abdominal adhesions, chronic abdominal pain syndrome, coccydynia, pelvic floor myalgia (levator ani spasm), polymyositis, postherpetic neuralgia, polyradiculoneuropathies, mononeuritis multiplex, reflex sympathetic dystrophy, neuropathic pain, vulvar vestibulitis, vulvodynia, chronic regional pain syndrome, osteoarthritis, fibrositis, chronic visceral pain syndrome, female urethral syndrome, painful diverticular disease, functional dyspepsia, nonulcer dyspepsia, non- erosive esophageal reflux disease, acid-sensitive esophagus, interstitial cystitis, chronic pelvic pain syndrome, chronic urethral syndrome, chronic prostatitis, primary dysmenorrhea!, dyspareunia, premenstrual syndrome (PMS), vulvodynia, ovarian remnant syndrome, ovulatory pain, pelvic congestion syndrome, myofasical pain syndrome, fibromyalgia polymyalgia rheumatica, Reiter's syndrome (reactive arthritis), rheumatoid arthritis, spondyloarthropathy, functional somatic syndromes, chronic regional pain syndromes, post polio syndrome, functional somatic syndrome, rhinitis, asthma, multiple chemical sensitivity syndrome, reactive airway dysfunction syndrome, dysnomia, sick building syndrome, asthma, idiopathic pulmonary fibrosis, idiopathic pulmonary hypertension, dysphagia, gastroparesis, functional diarrhea, chronic constipation, defecation dysfunction, dysuria, atonic bladder, neurogenic bladder, irritable bowel syndrome (IBS), ileus, chronic idiopathic pseudoobstruction, Ogilvie's syndrome, restless leg syndrome, immune dysfunction syndrome, multiple sclerosis (MS), eczema, psoriasis, atopic dermatitis, dermatitis, Crohn's disease, ulcerative colitis, ulcerative proctitis, pouchitis, nonspecific ulcerative colitis, inflammatory bowel disease (IBD), celiac disease, diversion colitis, collagenous colitis, lymphocytic colitis, blind loop syndrome, nonalcoholic steatohepatitis (NASH), fatty liver, chronic liver disease, cirrhosis, spontaneous bacterial peritonitis, postoperative ileus, systemic lupus erythematosis, mixed connective tissue disorder, undifferentiated connective tissue disorder, Raynaud's phenomenon, Kawasaki syndrome, polymyositis, dermatomyositis, myositis, multiple autoimmune syndrome, Sjogren's syndrome, lichen planus, idiopathic uveitis, gingivitis, stomatitis, otitis, necrotizing enterocolitis, intensive care unit (ICU) multiple organ failure, primary biliary cirrhosis, idiopathic myelofibrosis, polyarteritis nodosa, eosinophilic pleural effusion, eosinophilic gastroenteritis, eosinophilic esophagitis, graft vs. host disease, Grave's disease, idiopathic thyroid failure, Hashimoto's thyroiditis, autoimmune hepatitis, pancreatitis, CREST syndrome, autoimmune cholangitis, ankylosing spondylitis, atopic dermatitis, vitiligo, scleroderma, autoimmune ear disease, polyangiitis overlap syndrome, primary sclerosing cholangitis, Gulf War syndrome, myalgic encephalomyelitis, food sensitivity, dysregulation spectrum syndrome, post-traumatic stress disorder (PTSD), benign tumor, malignant tumor, cancer and combinations thereof. 17. The method of claim 15, wherein the detecting the presence and/or concentration of H2S comprises: detecting the presence and/or concentration of H2S in the mammal's breath and/or blood. 18. The method of claim 17, wherein the detecting the presence and/or concentration of H2S in the mammal's breath and/or blood comprises: providing a quantity of a poorly digestible sugar; administering the quantity of the poorly digestible sugar to the mammal; obtaining a breath sample and/or a blood sample from the mammal; and analyzing the breath sample and/or the blood sample to determine the presence and/or concentration of H2S. 19. The method of claim 18, wherein the poorly digestible sugar is selected from the group consisting of glucose, lactose, lactulose, xylose and combinations thereof. 20. The method of claim 18, wherein the analyzing the breath sample comprises: analyzing the breath sample using a gas analyzer sensitive to sulfur or sulfur containing compounds to determine the presence and/or concentration ofH2S. 21. The method of claim 18, wherein the analyzing the breath sample comprises: analyzing the breath sample using a total/species sulfur analyzer to determine the presence and/or concentration of H2S. 22. The method of claim 18, wherein the analyzing the blood sample further comprises: providing a quantity of zinc acetate; and adding the quantity of zinc acetate to the blood sample, whereby the quantity of zinc acetate traps the H2S in the blood. 23. The method of claim 18, wherein the analyzing the blood sample comprises: analyzing the blood sample using a colorimetric assay for H2S, a sulfide-sensitive electrode or spectrophotometry. 24. The method of claim 15, wherein detecting the presence and/or concentration of thiosulfate comprises: detecting the presence and/or concentration of thiosulfate in the mammal's blood and/or urine. 25. The method of claim 24, wherein the detecting the presence and/or concentration of thiosulfate in the mammal's blood and/or urine of the mammal comprises: providing a quantity of a poorly digestible sugar; administering the quantity of the poorly digestible sugar to the mammal; obtaining a blood sample and/or a urine sample from the mammal; and analyzing the blood sample and/or the urine sample for the presence and/or concentration of thiosulfate. 26. The method of claim 25, wherein the poorly digestible sugar is selected from the group consisting of glucose, lactose, lactulose, xylose and combinations thereof. 27. The method of claim 25, wherein the analyzing the blood sample and/or the urine sample comprises: analyzing the blood sample and/or the urine sample for the presence and/or concentration of thiosulfate using liquid chromatography. 28. The method of claim 27, wherein the liquid chromatography is reverse-phase ion-pair high performance liquid chromatography. 29. A kit for the treating a disease condition in a mammal with an elevated level of bacteria-'derived hydrogen sulfide (H2S), comprising: a therapeutic agent capable of at least partially eradicating bacterial overgrowth; and instructions to administer the therapeutic agent to the mammal to reduce bacteria- derived H2S in the mammal, wherein the disease condition is a disease condition related to a category selected from the group consisting of hypercoagulable states related to hyperhomocysteinemia, vasodilatatory states, interference with function as neurotransmitter, interference with endocrine function, chronic pain syndromes due to stimulation of N-methyl-D-aspartate (NMDA) receptors leading to hypersensitivity, injury to nasal and/or respiratory tract, interference with visceral smooth muscle contractile function, inhibition of aerobic metabolism/ischemia disorders, triggering of inflammation, overlap disorders, interference with regulation of apoptosis and proliferation and combinations thereof. 30. The kit of claim 29, wherein the disease condition is selected from the group consisting of hyperhomocysteinemia, chronic renal failure, end stage renal disease, hemodialysis, peritoneal dialysis, vascular dementia, cardiovascular disease, stroke, cerebrovascular accidents, thrombotic disorder, hypercoagulable states, venous thrombosis, deep vein thrombosis, thrombophlebitis, thromboembolic disease, ischemic stroke, restenosis after percutaneous transluminal coronary angioplasty (PTCA), preeclampsia, vasculitis, digital ischemia, multifocal osteonecrosis, retinal vein occlusion, glaucoma, miscarriage, pregnancy complication, placental abruption, transplantation, diabetic retinopathy, ischemic bowel disease, cerebral vein thrombosis, atherosclerosis, coronary artery disease, penile venous thrombosis, impotence, central venous thrombosis, peripheral artery disease, intermittent claudication, hemorrhagic colitis, radiation enteritis, radiation colitis, visceral ischemia, acute mesenteric ischemia, chronic mesenteric ischemia, hypertension, microangiopathy, macroangiopathy, recurrent leg ulcer, carotid stenosis, occlusive vascular disease, arterial aneurysm, abdominal aortic aneurysm, congestive heart failure, hepatopulmonary syndrome, high flow state associated with chronic liver disease, migraine headache, vascular headache, dizziness, lightheadedness, orthostatic intolerance, postural hypotension, postural hypotension, postural orthostatic tachycardia syndrome, idiopathic pulmonary fibrosis, pulmonary hypertension, angioedema, vasovagal faints, neuroleptic malignant syndrome, learning disorder, learning disability, insomnia, dementia, age associated memory impairment, attention deficit/hyperactivity disorder (ADHD), mild cognitive impairment, Alzheimer's disease, Down's syndrome, autism, Parkinson's disease, depression, anxiety or anxiety disorder, Asperger syndrome, glucose intolerance, diabetes, reactive hypoglycemia, metabolic syndrome, low Cortisol, hypothalamus-pituitary-adrenal dysfunction, myasthenia gravis syndrome, osteoporosis, autoimmune polyendocrine syndrome, chronic fatigue syndrome (CFS), central sensitivity syndrome, angina, syndrome X, chronic neck pain syndrome, chronic neuromuscular pain, osteoarthritis, muscle tension headache, chronic headache, cluster headache, temporalis tendonitis, sinusitis, atypical facial pain, trigeminal neuralgia, facial and neck pain syndrome, temperomandibular joint syndrome, idiopathic chronic low back pain, endometriosis, painful abdominal adhesions, chronic abdominal pain syndrome, coccydynia, pelvic floor myalgia (levator ani spasm), polymyositis, postherpetic neuralgia, polyradiculoneuropathies, mononeuritis multiplex, reflex sympathetic dystrophy, neuropathic pain, vulvar vestibulitis, vulvodynia, chronic regional pain syndrome, osteoarthritis, fibrositis, chronic visceral pain syndrome, female urethral syndrome, painful diverticular disease, functional dyspepsia, nonulcer dyspepsia, non-erosive esophageal reflux disease, acid-sensitive esophagus, interstitial cystitis, chronic pelvic pain syndrome, chronic urethral syndrome, chronic prostatitis, primary dysmenorrheal, dyspareunia, premenstrual syndrome (PMS), vulvodynia, ovarian remnant syndrome, ovulatory pain, pelvic congestion syndrome, myofasical pain syndrome, fibromyalgia polymyalgia rheumatica, Reiter's syndrome (reactive arthritis), rheumatoid arthritis, spondyloarthropathy, functionaLsomatic syndromes, chronic regional pain syndromes, post polio syndrome, functional somatic syndrome, rhinitis, asthma, multiple chemical sensitivity syndrome, reactive airway dysfunction syndrome, dysnomia, sick building syndrome, asthma, idiopathic pulmonary fibrosis, idiopathic pulmonary hypertension, dysphagia, gastroparesis, functional diarrhea, chronic constipation, defecation dysfunction, dysuria, atonic bladder, neurogenic bladder, irritable bowel syndrome (IBS), ileus, chronic idiopathic pseudoobstruction, Ogilvie's syndrome, restless leg syndrome, immune dysfunction syndrome, multiple sclerosis (MS), eczema, psoriasis, atopic dermatitis, dermatitis, Crohn's disease, ulcerative colitis, ulcerative proctitis, pouchitis, nonspecific ulcerative colitis, inflammatory bowel disease (IBD), celiac disease, diversion colitis, collagenous colitis, lymphocytic colitis, blind loop syndrome, nonalcoholic steatohepatitis (NASH), fatty liver, chronic liver disease, cirrhosis, spontaneous bacterial peritonitis, postoperative ileus, systemic lupus erythematosis, mixed connective tissue disorder, undifferentiated connective tissue disorder, Raynaud's phenomenon, Kawasaki syndrome, polymyositis, dermatomyositis, myositis, multiple autoimmune syndrome, Sjogren's syndrome, lichen planus, idiopathic uveitis, gingivitis, stomatitis, otitis, necrotizing enterocolitis, intensive care unit (ICU) multiple organ failure, primary biliary cirrhosis, idiopathic myelofibrosis, polyarteritis nodosa, eosinophilic pleural effusion, eosinophilic gastroenteritis, eosinophilic esophagitis, graft vs. host disease, Grave's disease, idiopathic thyroid failure, Hashimoto's thyroiditis, autoimmune hepatitis, pancreatitis, CREST syndrome, autoimmune cholangitis, ankylosing spondylitis, atopic dermatitis, vitiligo, scleroderma, autoimmune ear disease, polyangiitis overlap syndrome, primary sclerosing cholangitis, Gulf War syndrome, myalgic encephalomyelitis, food sensitivity, dysregulation spectrum syndrome, post-traumatic stress disorder (PTSD), benign tumor, malignant tumor, cancer and combinations thereof. 31. The kit of claim 29, wherein the composition is selected from the group consisting of a methanogenic bacterium, a antimicrobial agent, an antimicrobial chemotherapeutic agent, an intestinal lavage agent, an enema agent, a bismuth-containing compound, a compound that binds iron in the intestinal lumen, a compound that binds hydrogen sulfide, a probiotic agent, a prokinetic agent and combinations thereof. 32. A kit for diagnosing and/or determining a prognosis of a disease condition related to an elevated level of bacteria-derived hydrogen sulfide (H2S) in a mammal having at least one symptom associated with a suspected diagnosis of the disease condition, comprising: a poorly digestible sugar; and instructions to use the poorly digestible sugar to diagnose and/or determine a prognosis of the disease condition, wherein the disease condition is a disease condition related to a category selected from the group consisting of hypercoagulable states related to hyperhomocysteinemia, vasodilatator states, interference with function as neurotransmitter, interference with endocrine function, chronic pain syndromes due to stimulation of N-methyl-D-aspartate (NMDA) receptors leading to hypersensitivity, injury to nasal and/or respiratory tract, interference with visceral smooth muscle contractile function, inhibition of aerobic metabolism/ischemia disorders, triggering of inflammation, overlap disorders, interference with regulation of apoptosis and proliferation and combinations thereof. 33. The kit of claim 32, wherein the disease condition is selected from the group consisting of hyperhomocysteinemia, chronic renal failure, end stage renal disease, hemodialysis, peritoneal dialysis, vascular dementia, cardiovascular disease, stroke, cerebrovascular accidents, thrombotic disorder, hypercoagulable states, venous thrombosis, deep vein thrombosis, thrombophlebitis, thromboembolic disease, ischemic stroke, restenosis after percutaneous transluminal coronary angioplasty (PTCA), preeclampsia, vasculitis, digital ischemia, multifocal osteonecrosis, retinal vein occlusion, glaucoma, miscarriage, pregnancy complication, placental abruption, transplantation, diabetic retinopathy, ischemic bowel disease, cerebral vein thrombosis, atherosclerosis, coronary artery disease, penile venous thrombosis, impotence, central venous thrombosis, peripheral artery disease, intermittent claudication, hemorrhagic colitis, radiation enteritis, radiation colitis, visceral ischemia, acute mesenteric ischemia, chronic mesenteric ischemia, hypertension, microangiopathy, macroangiopathy, recurrent leg ulcer, carotid stenosis, occlusive vascular disease, arterial aneurysm, abdominal aortic aneurysm, congestive heart failure, hepatopulmonary syndrome, high flow state associated with chronic liver disease, migraine headache, vascular headache, dizziness, lightheadedness, orthostatic intolerance, postural hypotension, postural hypotension, postural orthostatic tachycardia syndrome, idiopathic pulmonary fibrosis, pulmonary hypertension, angioedema, vaso- vagal faints, neuroleptic malignant syndrome, learning disorder, learning disability, insomnia, dementia, age associated memory impairment, attention defϊcit/hyperactivity disorder (ADHD), mild cognitive impairment, Alzheimer's disease, Down's syndrome, autism, Parkinson's disease, depression, anxiety or anxiety disorder, Asperger syndrome, glucose intolerance, diabetes, reactive hypoglycemia, metabolic syndrome, low Cortisol, hypothalamus-pituitary-adrenal dysfunction, myasthenia gravis syndrome, osteoporosis, autoimmune polyendocrine syndrome, chronic fatigue syndrome (CFS), central sensitivity syndrome, angina, syndrome X, chronic neck pain syndrome, chronic neuromuscular pain, osteoarthritis, muscle tension headache, chronic headache, cluster headache,(...)
法律状态
(WO2006102536) LEGAL DETAILS FOR WO2006102536  Actual or expected expiration date=2008-09-23    Legal state=DEAD    Status=LAPSED     Event publication date=2006-03-23  Event code=WO/APP  Event indicator=Pos  Event type=Examination events  Application details  Application country=WO WOUS2006010641  Application date=2006-03-23  Standardized application number=2006WO-US10641     Event publication date=2006-09-28  Event code=WO/A2  Event type=Examination events  International application published without international search report  Publication country=WO  Publication number=WO2006102536  Publication stage Code=A2  Publication date=2006-09-28  Standardized publication number=WO2006102536     Event publication date=2007-05-03  Event code=WO/A3  Event indicator=Pos  Event type=Examination events  Later publication of ISR with revised front page  Publication country=WO  Publication number=WO2006102536  Publication stage Code=A3  Publication date=2007-05-03  Standardized publication number=WO2006102536     Event publication date=2008-09-23  Event code=WO/EETL  Event type=Event indicating Not In Force  PCT Application validity period expired. LEGAL DETAILS FOR DESIGNATED STATE DE  Actual or expected expiration date=2007-09-25    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=DE     Event publication date=2007-09-25  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=DE  LEGAL DETAILS FOR DESIGNATED STATE RU  Actual or expected expiration date=2007-10-23    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=RU     Event publication date=2007-10-23  Event code=WO/NENP  Event type=Event indicating Not In Force  Non-entry into the national phase in: Corresponding cc:  Designated or member state=RU  LEGAL DETAILS FOR DESIGNATED STATE US2009233888  Actual or expected expiration date=2010-10-08    Legal state=DEAD    Status=LAPSED   Corresponding cc:  Designated or member state=US Corresponding appl: US90914006  Application date in the designated or member state=2006-03-23   Application number in the designated or member state=2006US-11909140 Corresponding cc:  Designated or member state=US Corresponding pat: US2009233888  Publication stage code in the designated or member state=A1  Publication date in the designated or member state=2009-09-17   Publication number in the designated or member state=US20090233888    Event publication date=2007-09-19  Event code=WO/WWE  Event indicator=Pos  Event type=Entry into national phase  Wipo information: entry into national phase Corresponding cc:  Designated or member state=US     Event publication date=2010-10-08  Event code=US/STCHG  Patent Status changed by the national office Corresponding cc:  Designated or member state=US
专利类型码
A2A3
国别省市代码
若您需要申请原文,请登录。

最新评论

暂无评论。

登录后可以发表评论

意见反馈
返回顶部